Tamtam Try Tamtam free
Glanbia logo

Glanbia account plan

Better nutrition products

At a glance

Glanbia is an Irish nutrition group behind Optimum Nutrition and B2B nutrition ingredients, with FY2025 revenue of $3,946.4m and 5,800 employees.

Glanbia plc is an Irish nutrition group that sells sports and lifestyle nutrition brands (Optimum Nutrition, Isopure, think!) and B2B nutrition ingredients such as custom premixes, flavours, whey protein solutions and bioactives, plus American-style cheddar cheese in the US. Its brands and ingredients are sold in 120+ markets, from 27 manufacturing sites and 20 innovation and collaboration centres, and the US is its largest market with $2,660.5m of FY2025 revenue. In FY 2025 (52 weeks to 3 January 2026) revenue was $3,946.4m, pre-exceptional EBITDA $499.1m and profit after tax $183.3m, with 5,800 employees. Glanbia is listed, and Tirlán Co-op is its largest shareholder, with 13.18% after a directed buyback in June 2026.

Business units

Strategic priorities

Capital Markets Day targets 2026-2028
Adjusted EPS growth of 7-11% a year at constant currency, OCF conversion of 85%+, ROCE of 10-13% and a 30-40% dividend payout; organic revenue growth of 5-7% a year in Performance Nutrition and 4-6% in Health & Nutrition, and Dairy Nutrition EBITDA of $150-160m a year.
Grow Optimum Nutrition globally
Driving Optimum Nutrition is the first of five strategic priorities, backed by the global Optimum Advantage campaign and a double-digit dollar increase in marketing for the brand in 2026 and 2027.
Scale Health & Nutrition
Scale H&N as a solutions partner through mid-market customer acquisition, cross-selling, targeted acquisitions and capacity expansion in the US, China and Europe expected by early 2027.
Transformation savings
The group-wide transformation programme now targets $70m a year of savings by FY 2027 (raised from $60m), through supply chain centres of excellence, outsourced back-office functions, new Finance and HR systems and AI-enabled tools.
International expansion
Expand internationally and leverage global scale, including a 5% inventory reduction over three years; PN International grew like-for-like by 28.3% in the first nine months of 2026.

Latest results

In the nine months to 3 October 2026, group like-for-like revenue grew 9.9% (volume +4.2%, price +5.7%) to $3.2bn, and Performance Nutrition grew 18.0% like-for-like on pricing taken against whey inflation. In H1 2026 (six months to 4 July 2026), revenue was $2,079.4m, up 7.0% at constant currency, pre-exceptional EBITDA rose 14.1% to $275.4m and adjusted EPS rose 30.0% at constant currency. FY 2026 guidance was raised twice and now calls for adjusted EPS growth of 22-24% at constant currency, PN like-for-like growth of 16-17% and Dairy Nutrition EBITDA of $175-180m. Net debt was $704m at 3 October 2026.

Investments and deals

Health & Nutrition acquisitions
Sweetmix (Brazil premix) acquired in 2025 for initial consideration of $41.4m, and Scicore (India) completed in January 2026 for about $16.4m; management describes the M&A pipeline as very active, primarily in H&N.
Capacity expansion
A second building at the Suzhou, China premix plant to more than double capacity, a flavour spray-drying centre and a collaboration centre in Sharonville, and WPI capacity at the MWC-Southwest joint venture from early 2027; FY 2026 capex is guided at $100-110m.
Portfolio divestments
SlimFast and Body & Fit were divested in 2025, with a $45.7m loss on disposal.
Shareholder returns
€197.2m of buybacks in 2025 and a further €100m in 2026, half of it a directed buyback from Tirlán.

Challenges and risks

Whey input cost inflation
Record whey protein costs cut the Performance Nutrition EBITDA margin by 380bps to 13.0% in FY2025; whey for 2027 is procured at higher cost, so further price increases are expected in H1 2027.
Price elasticity
After three price increases in 12 months, PN volumes fell 4.7% in Q3 2026 on tough US comparatives, with elasticity concentrated in specific channels and pack sizes.
Tariffs and geopolitics
Geopolitical, economic, market disruption and cybersecurity risks are rated elevated; Middle East-related raw material costs weighed on the H&N margin, which fell 110bps in H1 2026.
Weaker brands in the portfolio
Isopure lost a club-channel listing and other portfolio brands declined in PN Americas; think! is due for a relaunch in Q2 2027.
Cybersecurity during digital transformation
The annual report flags new vulnerabilities from AI and emerging technologies and the need for controls during the digital transformation.

What leadership says

“We are reshaping Glanbia into a more focused, higher-growth nutrition business.”

Hugh McGuire, Chief Executive Officer · Annual Report and Financial Statements 2025, March 2026

“fundamentally, whey price drop is good for the group. We are a far bigger buyer of high-end whey proteins than we are a manufacturer”

Hugh McGuire, Chief Executive Officer · Q3 2026 interim management statement call, 4 November 2026

“Our task now is to accelerate the execution of our Capital Markets Day strategy, to ensure we deliver on a consistent basis over the coming years.”

Paul Duffy, Group Chair · Annual Report and Financial Statements 2025, March 2026

“We delivered volume and like-for-like revenue growth across all three segments, reflecting disciplined execution as we continue to navigate whey cost inflation within Performance Nutrition.”

Hugh McGuire, Chief Executive Officer · Half Year 2026 Results, 6 August 2026

Where a supplier can help

Protein ingredient supply and hedging
Tied to whey input cost inflation: alternative protein sources, procurement analytics or risk tools that reduce exposure to whey price swings.
Automation and AI in shared services
Tied to the transformation programme and its $70m savings target: back-office outsourcing, process automation, Finance and HR systems and AI-enabled tools.
Equipment and construction for new capacity
Tied to the capacity expansion in the US, China and Europe and $100-110m of FY 2026 capex: blending, spray-drying, packaging and plant engineering suppliers.
Pricing and revenue management
Tied to price elasticity: pack-size, promotion and channel analytics that help sustain volume after repeated price increases.
Security for a changing IT estate
Tied to the elevated cybersecurity risk during digital transformation: security services covering new systems and AI deployments.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Glanbia?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Glanbia

What does Glanbia do?

Glanbia sells sports and lifestyle nutrition brands led by Optimum Nutrition, supplies custom premixes, flavours and whey protein solutions to other brands, and markets American-style cheddar cheese in the US.

What is Glanbia's revenue?

FY 2025 revenue was $3,946.4m with pre-exceptional EBITDA of $499.1m. In H1 2026 revenue was $2,079.4m, up 7.0% at constant currency.

How many employees does Glanbia have?

Glanbia counts 5,800 employees, 27 manufacturing sites and 20 innovation and collaboration centres, including the joint venture.

What is Glanbia's strategy?

Five priorities: drive Optimum Nutrition, scale Health & Nutrition as a solutions partner, optimise Dairy Nutrition, expand internationally and innovate, supported by a transformation programme targeting $70m of annual savings by FY 2027.

Who leads Glanbia?

Hugh McGuire is CEO and Mark Garvey CFO; Wendy Chang Smith becomes CFO from 31 March 2027. Paul Duffy has been Group Chair since 1 January 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)